< Back one page or click on the timeline to continue your journey.

Overview

Sinemet® was developed by DuPont during the 1970s for the treatment of Parkinson’s disease. The product combines two drugs. One component, levdopa, replaces dopamine, a natural neurotransmitter that victims of the disease lack. The second component makes the product more effective by delaying the conversion of levdopa into dopamine until the drug passes into the brain. The product was greatly improved in 1991 when DuPont Merck Pharmaceutical Company received FDA approval to market Sinemet® /CR, a continuous release version in which the drug is suspended in a polymeric matrix that erodes slowly. Still marketed in both its new and older forms, the product remains the leading treatment for Parkinson’s Disease.

Top

< Back one page or click on the timeline to continue your journey.

Privacy | Contact Us |   

Copyright © 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003 E.I. du Pont de Nemours and Company. All rights reserved. The DuPont Oval logo, DuPont™, The miracles of science™ and all products denoted with ™ or ® are trademarks or registered trademarks of E.I. du Pont de Nemours and Company or its affiliates.

» Print this article